Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-2: KTE-X19 in relapsed/refractory mantle cell lymphoma
NL-OMON54549Phase 2Recruiting
- Sponsor
- Kite Pharma
- Start
- Jul 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of brexucabtagene autoleucel in mantle cell lymphoma (MCL) (3 cohorts), sponsored by Kite Pharma. Primary endpoint: Objective response rate. Started Jul 2018; status: recruiting.
02
Drugs
brexucabtagene autoleucel
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NL-OMON54549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54549.